Risk of liver‐related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease
Background and Aims Several guidelines recommend screening for NAFLD in patients with type 2 diabetes (T2D). We aimed to determine if there is a threshold of age and duration of T2D for liver‐related event development to guide screening strategies. Approach and Results We conducted a territory‐wide...
Saved in:
Published in | Hepatology (Baltimore, Md.) Vol. 76; no. 5; pp. 1409 - 1422 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken
Wolters Kluwer Health, Inc
01.11.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background and Aims
Several guidelines recommend screening for NAFLD in patients with type 2 diabetes (T2D). We aimed to determine if there is a threshold of age and duration of T2D for liver‐related event development to guide screening strategies.
Approach and Results
We conducted a territory‐wide retrospective cohort study of adult patients with NAFLD and T2D diagnosed between 2000 and 2014 in Hong Kong to allow for at least 5 years of follow‐up. The primary endpoint was liver‐related events, defined as a composite of HCC and cirrhotic complications. This study included 7028 patients with NAFLD with T2D (mean age, 56.1 ± 13.3 years; 3363 male [47.9%]). During a follow‐up of 77,308 person‐years, there was a threshold effect with 1.1%, 4.9%, and 94.0% of patients developing liver‐related events at the age of <40, 40–50, and ≥50 years, respectively. Similarly, 3.1%, 5.1%, and 91.8% of patients developed cirrhosis at the age of <40, 40–50, and ≥50 years, respectively. In contrast, liver‐related events increased linearly with diabetes duration, with no difference in the annual incidence rate between the first 10 years of T2D diagnosis and subsequent years (0.06% vs. 0.10%; p = 0.136). On multivariable analysis, baseline age ≥50 years (adjusted HR [aHR] 2.01) and cirrhosis (aHR 3.12) were the strongest risk factors associated with liver‐related events. Substitution of cirrhosis with the aspartate aminotransferase‐to‐platelet ratio index or the Fibrosis‐4 index yielded similar results.
Conclusions
Age rather than duration of T2D predicts liver‐related events in patients with NAFLD and T2D. It is reasonable to screen patients with NAFLD and T2D for advanced liver disease starting at 50 years of age.
Diabetes is an important risk factor for nonalcoholic fatty liver disease (NAFLD) and its severity. However, it is difficult to screen every diabetic patient for NAFLD because of the large number of patients. In a study of 7028 patients with NAFLD and type 2 diabetes from Hong Kong, we showed that the vast majority of patients developed liver‐related complications after the age of 50 years. In contrast, liver‐related events increased linearly with the duration of diabetes with no threshold effect. Our study suggests that screening for liver disease should be based on age instead of the duration of diabetes. |
---|---|
AbstractList | Several guidelines recommend screening for NAFLD in patients with type 2 diabetes (T2D). We aimed to determine if there is a threshold of age and duration of T2D for liver-related event development to guide screening strategies.BACKGROUND AND AIMSSeveral guidelines recommend screening for NAFLD in patients with type 2 diabetes (T2D). We aimed to determine if there is a threshold of age and duration of T2D for liver-related event development to guide screening strategies.We conducted a territory-wide retrospective cohort study of adult patients with NAFLD and T2D diagnosed between 2000 and 2014 in Hong Kong to allow for at least 5 years of follow-up. The primary endpoint was liver-related events, defined as a composite of HCC and cirrhotic complications. This study included 7028 patients with NAFLD with T2D (mean age, 56.1 ± 13.3 years; 3363 male [47.9%]). During a follow-up of 77,308 person-years, there was a threshold effect with 1.1%, 4.9%, and 94.0% of patients developing liver-related events at the age of <40, 40-50, and ≥50 years, respectively. Similarly, 3.1%, 5.1%, and 91.8% of patients developed cirrhosis at the age of <40, 40-50, and ≥50 years, respectively. In contrast, liver-related events increased linearly with diabetes duration, with no difference in the annual incidence rate between the first 10 years of T2D diagnosis and subsequent years (0.06% vs. 0.10%; p = 0.136). On multivariable analysis, baseline age ≥50 years (adjusted HR [aHR] 2.01) and cirrhosis (aHR 3.12) were the strongest risk factors associated with liver-related events. Substitution of cirrhosis with the aspartate aminotransferase-to-platelet ratio index or the Fibrosis-4 index yielded similar results.APPROACH AND RESULTSWe conducted a territory-wide retrospective cohort study of adult patients with NAFLD and T2D diagnosed between 2000 and 2014 in Hong Kong to allow for at least 5 years of follow-up. The primary endpoint was liver-related events, defined as a composite of HCC and cirrhotic complications. This study included 7028 patients with NAFLD with T2D (mean age, 56.1 ± 13.3 years; 3363 male [47.9%]). During a follow-up of 77,308 person-years, there was a threshold effect with 1.1%, 4.9%, and 94.0% of patients developing liver-related events at the age of <40, 40-50, and ≥50 years, respectively. Similarly, 3.1%, 5.1%, and 91.8% of patients developed cirrhosis at the age of <40, 40-50, and ≥50 years, respectively. In contrast, liver-related events increased linearly with diabetes duration, with no difference in the annual incidence rate between the first 10 years of T2D diagnosis and subsequent years (0.06% vs. 0.10%; p = 0.136). On multivariable analysis, baseline age ≥50 years (adjusted HR [aHR] 2.01) and cirrhosis (aHR 3.12) were the strongest risk factors associated with liver-related events. Substitution of cirrhosis with the aspartate aminotransferase-to-platelet ratio index or the Fibrosis-4 index yielded similar results.Age rather than duration of T2D predicts liver-related events in patients with NAFLD and T2D. It is reasonable to screen patients with NAFLD and T2D for advanced liver disease starting at 50 years of age.CONCLUSIONSAge rather than duration of T2D predicts liver-related events in patients with NAFLD and T2D. It is reasonable to screen patients with NAFLD and T2D for advanced liver disease starting at 50 years of age. Background and Aims Several guidelines recommend screening for NAFLD in patients with type 2 diabetes (T2D). We aimed to determine if there is a threshold of age and duration of T2D for liver‐related event development to guide screening strategies. Approach and Results We conducted a territory‐wide retrospective cohort study of adult patients with NAFLD and T2D diagnosed between 2000 and 2014 in Hong Kong to allow for at least 5 years of follow‐up. The primary endpoint was liver‐related events, defined as a composite of HCC and cirrhotic complications. This study included 7028 patients with NAFLD with T2D (mean age, 56.1 ± 13.3 years; 3363 male [47.9%]). During a follow‐up of 77,308 person‐years, there was a threshold effect with 1.1%, 4.9%, and 94.0% of patients developing liver‐related events at the age of <40, 40–50, and ≥50 years, respectively. Similarly, 3.1%, 5.1%, and 91.8% of patients developed cirrhosis at the age of <40, 40–50, and ≥50 years, respectively. In contrast, liver‐related events increased linearly with diabetes duration, with no difference in the annual incidence rate between the first 10 years of T2D diagnosis and subsequent years (0.06% vs. 0.10%; p = 0.136). On multivariable analysis, baseline age ≥50 years (adjusted HR [aHR] 2.01) and cirrhosis (aHR 3.12) were the strongest risk factors associated with liver‐related events. Substitution of cirrhosis with the aspartate aminotransferase‐to‐platelet ratio index or the Fibrosis‐4 index yielded similar results. Conclusions Age rather than duration of T2D predicts liver‐related events in patients with NAFLD and T2D. It is reasonable to screen patients with NAFLD and T2D for advanced liver disease starting at 50 years of age. Diabetes is an important risk factor for nonalcoholic fatty liver disease (NAFLD) and its severity. However, it is difficult to screen every diabetic patient for NAFLD because of the large number of patients. In a study of 7028 patients with NAFLD and type 2 diabetes from Hong Kong, we showed that the vast majority of patients developed liver‐related complications after the age of 50 years. In contrast, liver‐related events increased linearly with the duration of diabetes with no threshold effect. Our study suggests that screening for liver disease should be based on age instead of the duration of diabetes. Background and AimsSeveral guidelines recommend screening for NAFLD in patients with type 2 diabetes (T2D). We aimed to determine if there is a threshold of age and duration of T2D for liver‐related event development to guide screening strategies.Approach and ResultsWe conducted a territory‐wide retrospective cohort study of adult patients with NAFLD and T2D diagnosed between 2000 and 2014 in Hong Kong to allow for at least 5 years of follow‐up. The primary endpoint was liver‐related events, defined as a composite of HCC and cirrhotic complications. This study included 7028 patients with NAFLD with T2D (mean age, 56.1 ± 13.3 years; 3363 male [47.9%]). During a follow‐up of 77,308 person‐years, there was a threshold effect with 1.1%, 4.9%, and 94.0% of patients developing liver‐related events at the age of <40, 40–50, and ≥50 years, respectively. Similarly, 3.1%, 5.1%, and 91.8% of patients developed cirrhosis at the age of <40, 40–50, and ≥50 years, respectively. In contrast, liver‐related events increased linearly with diabetes duration, with no difference in the annual incidence rate between the first 10 years of T2D diagnosis and subsequent years (0.06% vs. 0.10%; p = 0.136). On multivariable analysis, baseline age ≥50 years (adjusted HR [aHR] 2.01) and cirrhosis (aHR 3.12) were the strongest risk factors associated with liver‐related events. Substitution of cirrhosis with the aspartate aminotransferase‐to‐platelet ratio index or the Fibrosis‐4 index yielded similar results.ConclusionsAge rather than duration of T2D predicts liver‐related events in patients with NAFLD and T2D. It is reasonable to screen patients with NAFLD and T2D for advanced liver disease starting at 50 years of age. |
Author | Yip, Terry Cheuk‐Fung Zhang, Xinrong Wong, Vincent Wai‐Sun Lai, Jimmy Che‐To Tse, Yee‐Kit Chan, Henry Lik‐Yuen Hui, Vicki Wing‐Ki Kong, Alice Pik‐Shan Lin, Huapeng Cheung, Johnny T. K. Wong, Grace Lai‐Hung |
Author_xml | – sequence: 1 givenname: Xinrong orcidid: 0000-0002-8393-8904 surname: Zhang fullname: Zhang, Xinrong organization: The Chinese University of Hong Kong – sequence: 2 givenname: Grace Lai‐Hung orcidid: 0000-0002-2863-9389 surname: Wong fullname: Wong, Grace Lai‐Hung organization: The Chinese University of Hong Kong – sequence: 3 givenname: Terry Cheuk‐Fung surname: Yip fullname: Yip, Terry Cheuk‐Fung organization: The Chinese University of Hong Kong – sequence: 4 givenname: Johnny T. K. orcidid: 0000-0001-7455-5218 surname: Cheung fullname: Cheung, Johnny T. K. organization: The Chinese University of Hong Kong – sequence: 5 givenname: Yee‐Kit surname: Tse fullname: Tse, Yee‐Kit organization: The Chinese University of Hong Kong – sequence: 6 givenname: Vicki Wing‐Ki surname: Hui fullname: Hui, Vicki Wing‐Ki organization: The Chinese University of Hong Kong – sequence: 7 givenname: Huapeng surname: Lin fullname: Lin, Huapeng organization: The Chinese University of Hong Kong – sequence: 8 givenname: Jimmy Che‐To surname: Lai fullname: Lai, Jimmy Che‐To organization: The Chinese University of Hong Kong – sequence: 9 givenname: Henry Lik‐Yuen surname: Chan fullname: Chan, Henry Lik‐Yuen organization: Union Hospital – sequence: 10 givenname: Alice Pik‐Shan surname: Kong fullname: Kong, Alice Pik‐Shan organization: The Chinese University of Hong Kong – sequence: 11 givenname: Vincent Wai‐Sun orcidid: 0000-0003-2215-9410 surname: Wong fullname: Wong, Vincent Wai‐Sun email: wongv@cuhk.edu.hk organization: The Chinese University of Hong Kong |
BookMark | eNp10UtKBDEQBuAgCo6PhTcIuNFFayX9Si9FfIGgiK6bpLviRGNnTDIO48ojeEZPYpwRBNFVsvj-Sqpqg6wObkBCdhgcMAB-OMbJQc6LulohI1byOsvzElbJCHgNWcPyZp1shPAAAE3BxYi83pjwSJ2m1ryg_3h792hlxJ7iCw4xUDWn8h6pHHraG6kwYqD91Mto3EDNQCfptoAzE8c_5Munn0nbubGzpqNaxjhfPpJUQBlwi6xpaQNuf5-b5O705Pb4PLu8Ors4PrrMurwSVSYKwVilGBMAVaMUKF73kislgGtd6B5KrVKXumGCLyJMoBJlx-saCuT5Jtlb1p149zzFENsnEzq0Vg7opqHlVVEAB17mie7-og9u6lMbSdW8bETDiyqpw6XqvAvBo247ExcTiV4a2zJov3bRpl20i12kxP6vxMSbJ-nnf9rv6jNjcf4_bM9PrpeJT2aOm-E |
CitedBy_id | crossref_primary_10_1111_liv_15718 crossref_primary_10_1097_HEP_0000000000000432 crossref_primary_10_1053_j_gastro_2023_06_008 crossref_primary_10_3390_biomedicines11041097 crossref_primary_10_1016_j_jceh_2025_102536 crossref_primary_10_15212_CVIA_2023_0073 crossref_primary_10_1111_liv_15880 crossref_primary_10_1002_ueg2_12514 crossref_primary_10_1002_poh2_31 crossref_primary_10_1097_HC9_0000000000000148 crossref_primary_10_1038_s41598_024_64928_2 crossref_primary_10_1053_j_gastro_2023_01_040 crossref_primary_10_7759_cureus_49286 crossref_primary_10_1002_mco2_781 crossref_primary_10_1111_hepr_14133 crossref_primary_10_1016_j_jhepr_2023_100791 crossref_primary_10_1159_000541945 crossref_primary_10_55544_jrasb_2_6_15 crossref_primary_10_1136_gutjnl_2023_330269 crossref_primary_10_3389_fendo_2023_1199429 crossref_primary_10_3390_jpm14010061 crossref_primary_10_3390_ijms26010050 crossref_primary_10_1016_j_jhep_2023_04_036 crossref_primary_10_1111_liv_16120 crossref_primary_10_1136_bmjopen_2023_080549 crossref_primary_10_1007_s10620_024_08723_z crossref_primary_10_1038_s41572_025_00599_1 crossref_primary_10_1002_ueg2_12508 crossref_primary_10_1016_j_mcna_2022_12_003 crossref_primary_10_3390_biomedicines11092416 crossref_primary_10_47102_annals_acadmedsg_2022284 crossref_primary_10_1016_j_heliyon_2024_e37869 crossref_primary_10_31146_1682_8658_ecg_223_3_25_32 crossref_primary_10_3350_cmh_2023_0066 crossref_primary_10_1097_HEP_0000000000000812 |
Cites_doi | 10.1056/NEJMoa1912035 10.1002/hep.28431 10.1007/s00125-021-05585-2 10.1111/liv.14638 10.1111/jvh.13307 10.1016/j.ejim.2020.08.005 10.1038/s41575-018-0014-9 10.1111/j.1478-3231.2011.02482.x 10.1016/j.jhep.2020.06.007 10.1002/hep.31142 10.1016/j.cgh.2014.04.014 10.1016/j.cgh.2017.02.031 10.1007/s00535-020-01754-z 10.1002/hep.30858 10.1136/gutjnl-2015-309265 10.1016/j.jhep.2015.11.004 10.1016/j.jhep.2019.03.033 10.1002/cncr.24982 10.1111/apt.14172 10.1002/sim.7501 10.1002/hep4.1705 10.1007/s00535-010-0310-9 10.1053/j.gastro.2018.04.034 10.1136/gutjnl-2011-300342 10.1002/hep.31726 10.1002/hep.29367 10.1002/hep.29660 |
ContentType | Journal Article |
Copyright | 2022 American Association for the Study of Liver Diseases. |
Copyright_xml | – notice: 2022 American Association for the Study of Liver Diseases. |
DBID | AAYXX CITATION 7T5 7TM 7TO 7U9 H94 K9. 7X8 |
DOI | 10.1002/hep.32476 |
DatabaseName | CrossRef Immunology Abstracts Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitle | CrossRef AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts Nucleic Acids Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic AIDS and Cancer Research Abstracts |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1527-3350 |
EndPage | 1422 |
ExternalDocumentID | 10_1002_hep_32476 HEP32476 |
Genre | article |
GrantInformation_xml | – fundername: The Chinese University of Hong Kong funderid: 2020.045 |
GroupedDBID | --- --K .3N .55 .GA .GJ .Y3 05W 0R~ 10A 186 1B1 1CY 1L6 1OB 1OC 1ZS 1~5 24P 31~ 33P 3O- 3SF 3WU 4.4 4G. 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5RE 5VS 7-5 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAEDT AAESR AAEVG AAHHS AALRI AANHP AAONW AAQFI AAQQT AAQXK AASGY AAXRX AAXUO AAZKR ABCQN ABCUV ABEML ABIJN ABLJU ABMAC ABOCM ABPVW ABWVN ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACLDA ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADEOM ADIZJ ADKYN ADMGS ADMUD ADNMO ADOZA ADXAS ADZMN ADZOD AECAP AEEZP AEIMD AENEX AEQDE AEUQT AFBPY AFFNX AFGKR AFPWT AFUWQ AFZJQ AHMBA AIACR AIURR AIWBW AJAOE AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EBS EJD F00 F01 F04 F5P FD8 FDB FEDTE FGOYB FUBAC G-S G.N GNP GODZA H.X HBH HF~ HHY HHZ HVGLF HZ~ IHE IX1 J0M J5H JPC KBYEO KQQ LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M41 M65 MJL MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N4W N9A NF~ NNB NQ- O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K R2- RGB RIG RIWAO RJQFR ROL RPZ RWI RX1 RYL SEW SSZ SUPJJ TEORI UB1 V2E V9Y W2D W8V W99 WBKPD WH7 WHWMO WIB WIH WIJ WIK WIN WJL WOHZO WQJ WRC WUP WVDHM WXI X7M XG1 XV2 ZGI ZXP ZZTAW ~IA ~WT AAYXX ABJNI ACZKN AFNMH AGQPQ AHQVU CITATION MEWTI WXSBR 7T5 7TM 7TO 7U9 AAMMB ADSXY AEFGJ AGXDD AIDQK AIDYY H94 K9. 7X8 |
ID | FETCH-LOGICAL-c3686-848116b1180069bb0b27da2bb802ff4fd05fb335f9182c368618eb85c27704e23 |
IEDL.DBID | DR2 |
ISSN | 0270-9139 1527-3350 |
IngestDate | Thu Jul 10 22:31:56 EDT 2025 Wed Aug 13 05:02:15 EDT 2025 Tue Jul 01 03:34:03 EDT 2025 Thu Apr 24 23:09:10 EDT 2025 Wed Jan 22 16:23:51 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3686-848116b1180069bb0b27da2bb802ff4fd05fb335f9182c368618eb85c27704e23 |
Notes | Funding information This study was supported in part by a direct grant from The Chinese University of Hong Kong (2020.045) ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0001-7455-5218 0000-0003-2215-9410 0000-0002-8393-8904 0000-0002-2863-9389 |
PQID | 2725989246 |
PQPubID | 996352 |
PageCount | 14 |
ParticipantIDs | proquest_miscellaneous_2644020253 proquest_journals_2725989246 crossref_citationtrail_10_1002_hep_32476 crossref_primary_10_1002_hep_32476 wiley_primary_10_1002_hep_32476_HEP32476 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | November 2022 2022-11-00 20221101 |
PublicationDateYYYYMMDD | 2022-11-01 |
PublicationDate_xml | – month: 11 year: 2022 text: November 2022 |
PublicationDecade | 2020 |
PublicationPlace | Hoboken |
PublicationPlace_xml | – name: Hoboken |
PublicationTitle | Hepatology (Baltimore, Md.) |
PublicationYear | 2022 |
Publisher | Wolters Kluwer Health, Inc |
Publisher_xml | – name: Wolters Kluwer Health, Inc |
References | 2015; 13 2012; 61 2017; 7 2021; 5 2019; 71 2020; 382 2020; 40 2020; 82 2017; 46 2011; 31 2022; 65 2018; 67 2021; 74 2010; 45 2018; 155 2017; 96 2021; 12 2021; 56 2017; 15 2017; 36 2010; 116 2021 2020; 73 2020; 72 2020; 71 2016; 65 2015; 2015 2016; 64 2020; 27 2018; 15 (hep32476-bib-0006-20241017) 2018; 67 (hep32476-bib-0009-20241017) 2010; 116 (hep32476-bib-0014-20241017) 2021; 5 (hep32476-bib-0025-20241017) 2020; 382 (hep32476-bib-0023-20241017) 2020; 73 (hep32476-bib-0026-20241017) 2021; 12 (hep32476-bib-0011-20241017) 2021 (hep32476-bib-0029-20241017) 2010; 45 (hep32476-bib-0004-20241017) 2020; 72 (hep32476-bib-0013-20241017) 2018; 15 (hep32476-bib-0019-20241017) 2017; 96 (hep32476-bib-0008-20241017) 2015; 2015 (hep32476-bib-0015-20241017) 2017; 36 (hep32476-bib-0033-20241017) 2012; 61 (hep32476-bib-0003-20241017) 2016; 65 (hep32476-bib-0016-20241017) 2011; 31 (hep32476-bib-0028-20241017) 2020; 27 (hep32476-bib-0024-20241017) 2019; 71 (hep32476-bib-0021-20241017) 2020; 82 (hep32476-bib-0001-20241017) 2016; 64 (hep32476-bib-0020-20241017) 2015; 13 (hep32476-bib-0031-20241017) 2017; 46 (hep32476-bib-0012-20241017) 2021; 74 (hep32476-bib-0005-20241017) 2016; 64 (hep32476-bib-0030-20241017) 2021; 56 (hep32476-bib-0007-20241017) 2017; 15 (hep32476-bib-0027-20241017) 2017; 7 (hep32476-bib-0010-20241017) 2018; 67 (hep32476-bib-0022-20241017) 2018; 155 (hep32476-bib-0002-20241017) 2020; 40 (hep32476-bib-0018-20241017) 2022; 65 (hep32476-bib-0032-20241017) 2021; 74 (hep32476-bib-0017-20241017) 2020; 71 |
References_xml | – volume: 36 start-page: 4391 issue: 27 year: 2017 end-page: 400 article-title: Practical recommendations for reporting Fine‐Gray model analyses for competing risk data publication-title: Stat Med – volume: 65 start-page: 1359 issue: 8 year: 2016 end-page: 68 article-title: Screening diabetic patients for non‐alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study publication-title: Gut – volume: 5 start-page: 1212 issue: 7 year: 2021 end-page: 23 article-title: Colonoscopy and risk of colorectal cancer in patients with nonalcoholic fatty liver disease: a retrospective territory‐wide cohort study publication-title: Hepatol Commun – volume: 56 start-page: 261 issue: 3 year: 2021 end-page: 73 article-title: Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan publication-title: J Gastroenterol – volume: 96 issue: 13 year: 2017 article-title: Diabetes mellitus increases the risk of hepatocellular carcinoma in treatment‐naïve chronic hepatitis C patients in China publication-title: Medicine – volume: 65 start-page: 3 issue: 1 year: 2022 end-page: 13 article-title: Interpreting global trends in type 2 diabetes complications and mortality publication-title: Diabetologia – volume: 15 start-page: 1453 issue: 9 year: 2017 end-page: 60.e1 article-title: Diagnostic accuracy of noninvasive fibrosis scores in a population of individuals with a low prevalence of fibrosis publication-title: Clin Gastroenterol Hepatol – volume: 73 start-page: 1023 issue: 5 year: 2020 end-page: 9 article-title: Repeated FIB‐4 measurements can help identify individuals at risk of severe liver disease publication-title: J Hepatol – volume: 12 issue: 3 year: 2021 article-title: Aspirin reduces the incidence of hepatocellular carcinoma in patients with chronic hepatitis B receiving oral nucleos(t)ide analog publication-title: Clin Transl Gastroenterol – year: 2021 article-title: Angiotensin‐converting enzyme inhibitors prevent liver‐related events in nonalcoholic fatty liver disease publication-title: Hepatology – volume: 31 start-page: 700 issue: 5 year: 2011 end-page: 6 article-title: Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors publication-title: Liver Int – volume: 71 start-page: 371 issue: 2 year: 2019 end-page: 78 article-title: Prospective evaluation of a primary care referral pathway for patients with non‐alcoholic fatty liver disease publication-title: J Hepatol – volume: 64 start-page: 73 issue: 1 year: 2016 end-page: 84 article-title: Global epidemiology of nonalcoholic fatty liver disease‐Meta‐analytic assessment of prevalence, incidence, and outcomes publication-title: Hepatology – volume: 382 start-page: 1018 issue: 11 year: 2020 end-page: 28 article-title: Association of aspirin with hepatocellular carcinoma and liver‐related mortality publication-title: N Engl J Med – volume: 45 start-page: 1097 issue: 11 year: 2010 end-page: 102 article-title: Mechanisms by which thiazolidinediones induce anti‐cancer effects in cancers in digestive organs publication-title: J Gastroenterol – volume: 13 start-page: 643 issue: 4 year: 2015 end-page: 54.e9 article-title: Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta‐analysis of paired‐biopsy studies publication-title: Clin Gastroenterol Hepatol – volume: 67 start-page: 1797 issue: 5 year: 2018 end-page: 806 article-title: Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: results from two prospective cohort studies publication-title: Hepatology – volume: 15 start-page: 461 issue: 8 year: 2018 end-page: 78 article-title: Noninvasive biomarkers in NAFLD and NASH ‐ current progress and future promise publication-title: Nat Rev Gastroenterol Hepatol – volume: 155 start-page: 443 issue: 2 year: 2018 end-page: 57.e417 article-title: Fibrosis severity as a determinant of cause‐specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi‐national cohort study publication-title: Gastroenterology – volume: 71 start-page: 907 issue: 3 year: 2020 end-page: 16 article-title: Diabetes is associated with increased risk of hepatocellular carcinoma in patients with cirrhosis from nonalcoholic fatty liver disease publication-title: Hepatology – volume: 116 start-page: 1938 issue: 8 year: 2010 end-page: 46 article-title: Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma publication-title: Cancer – volume: 74 start-page: 474 issue: 1 year: 2021 end-page: 82 article-title: Administrative coding in electronic health care record‐based research of NAFLD: an expert panel consensus statement publication-title: Hepatology – volume: 7 start-page: 1606 issue: 7 year: 2017 end-page: 16 article-title: The role of thiazolidinediones in hepatocellular carcinoma risk reduction: a population‐based cohort study in Taiwan publication-title: Am J Cancer Res – volume: 61 start-page: 409 issue: 3 year: 2012 end-page: 15 article-title: Prevalence of non‐alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton‐magnetic resonance spectroscopy and transient elastography publication-title: Gut – volume: 27 start-page: 904 issue: 9 year: 2020 end-page: 14 article-title: Thiazolidinediones reduce the risk of hepatocellular carcinoma and hepatic events in diabetic patients with chronic hepatitis B publication-title: J Viral Hepat – volume: 72 start-page: 1230 issue: 4 year: 2020 end-page: 241 article-title: Serial transient elastography examinations to monitor patients with type 2 diabetes: a prospective cohort study publication-title: Hepatology – volume: 74 start-page: 928 issue: S1 year: 2021 end-page: 9 article-title: Accuracy of administrative coding for nonalcoholic fatty liver disease and related hepatic complications: a single‐center validation study publication-title: Hepatology – volume: 46 start-page: 447 issue: 4 year: 2017 end-page: 56 article-title: Laboratory parameter‐based machine learning model for excluding non‐alcoholic fatty liver disease (NAFLD) in the general population publication-title: Aliment Pharmacol Ther – volume: 40 start-page: 2719 issue: 11 year: 2020 end-page: 31 article-title: Unhealthy lifestyle habits and physical inactivity among Asian patients with non‐alcoholic fatty liver disease publication-title: Liver Int – volume: 2015 year: 2015 article-title: Diabetes and insulin therapy, but not metformin, are related to hepatocellular cancer risk publication-title: Gastroenterol Res Pract – volume: 67 start-page: 328 issue: 1 year: 2018 end-page: 57 article-title: The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases publication-title: Hepatology – volume: 64 start-page: 1388 issue: 6 year: 2016 end-page: 402 article-title: EASL‐EASD‐EASO clinical practice guidelines for the management of non‐alcoholic fatty liver disease publication-title: J Hepatol – volume: 82 start-page: 68 year: 2020 end-page: 75 article-title: Screening for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography ‐ a prospective, cross sectional study publication-title: Eur J Intern Med – volume: 382 start-page: 1018 issue: 11 year: 2020 ident: hep32476-bib-0025-20241017 article-title: Association of aspirin with hepatocellular carcinoma and liver‐related mortality publication-title: N Engl J Med doi: 10.1056/NEJMoa1912035 – volume: 64 start-page: 73 issue: 1 year: 2016 ident: hep32476-bib-0001-20241017 article-title: Global epidemiology of nonalcoholic fatty liver disease‐Meta‐analytic assessment of prevalence, incidence, and outcomes publication-title: Hepatology doi: 10.1002/hep.28431 – year: 2021 ident: hep32476-bib-0011-20241017 article-title: Angiotensin‐converting enzyme inhibitors prevent liver‐related events in nonalcoholic fatty liver disease publication-title: Hepatology – volume: 96 issue: 13 year: 2017 ident: hep32476-bib-0019-20241017 article-title: Diabetes mellitus increases the risk of hepatocellular carcinoma in treatment‐naïve chronic hepatitis C patients in China publication-title: Medicine – volume: 65 start-page: 3 issue: 1 year: 2022 ident: hep32476-bib-0018-20241017 article-title: Interpreting global trends in type 2 diabetes complications and mortality publication-title: Diabetologia doi: 10.1007/s00125-021-05585-2 – volume: 40 start-page: 2719 issue: 11 year: 2020 ident: hep32476-bib-0002-20241017 article-title: Unhealthy lifestyle habits and physical inactivity among Asian patients with non‐alcoholic fatty liver disease publication-title: Liver Int doi: 10.1111/liv.14638 – volume: 27 start-page: 904 issue: 9 year: 2020 ident: hep32476-bib-0028-20241017 article-title: Thiazolidinediones reduce the risk of hepatocellular carcinoma and hepatic events in diabetic patients with chronic hepatitis B publication-title: J Viral Hepat doi: 10.1111/jvh.13307 – volume: 82 start-page: 68 year: 2020 ident: hep32476-bib-0021-20241017 article-title: Screening for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography ‐ a prospective, cross sectional study publication-title: Eur J Intern Med doi: 10.1016/j.ejim.2020.08.005 – volume: 15 start-page: 461 issue: 8 year: 2018 ident: hep32476-bib-0013-20241017 article-title: Noninvasive biomarkers in NAFLD and NASH ‐ current progress and future promise publication-title: Nat Rev Gastroenterol Hepatol doi: 10.1038/s41575-018-0014-9 – volume: 31 start-page: 700 issue: 5 year: 2011 ident: hep32476-bib-0016-20241017 article-title: Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors publication-title: Liver Int doi: 10.1111/j.1478-3231.2011.02482.x – volume: 73 start-page: 1023 issue: 5 year: 2020 ident: hep32476-bib-0023-20241017 article-title: Repeated FIB‐4 measurements can help identify individuals at risk of severe liver disease publication-title: J Hepatol doi: 10.1016/j.jhep.2020.06.007 – volume: 72 start-page: 1230 issue: 4 year: 2020 ident: hep32476-bib-0004-20241017 article-title: Serial transient elastography examinations to monitor patients with type 2 diabetes: a prospective cohort study publication-title: Hepatology doi: 10.1002/hep.31142 – volume: 7 start-page: 1606 issue: 7 year: 2017 ident: hep32476-bib-0027-20241017 article-title: The role of thiazolidinediones in hepatocellular carcinoma risk reduction: a population‐based cohort study in Taiwan publication-title: Am J Cancer Res – volume: 13 start-page: 643 issue: 4 year: 2015 ident: hep32476-bib-0020-20241017 article-title: Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta‐analysis of paired‐biopsy studies publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2014.04.014 – volume: 15 start-page: 1453 issue: 9 year: 2017 ident: hep32476-bib-0007-20241017 article-title: Diagnostic accuracy of noninvasive fibrosis scores in a population of individuals with a low prevalence of fibrosis publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2017.02.031 – volume: 74 start-page: 928 issue: S1 year: 2021 ident: hep32476-bib-0012-20241017 article-title: Accuracy of administrative coding for nonalcoholic fatty liver disease and related hepatic complications: a single‐center validation study publication-title: Hepatology – volume: 56 start-page: 261 issue: 3 year: 2021 ident: hep32476-bib-0030-20241017 article-title: Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan publication-title: J Gastroenterol doi: 10.1007/s00535-020-01754-z – volume: 71 start-page: 907 issue: 3 year: 2020 ident: hep32476-bib-0017-20241017 article-title: Diabetes is associated with increased risk of hepatocellular carcinoma in patients with cirrhosis from nonalcoholic fatty liver disease publication-title: Hepatology doi: 10.1002/hep.30858 – volume: 65 start-page: 1359 issue: 8 year: 2016 ident: hep32476-bib-0003-20241017 article-title: Screening diabetic patients for non‐alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study publication-title: Gut doi: 10.1136/gutjnl-2015-309265 – volume: 64 start-page: 1388 issue: 6 year: 2016 ident: hep32476-bib-0005-20241017 article-title: EASL‐EASD‐EASO clinical practice guidelines for the management of non‐alcoholic fatty liver disease publication-title: J Hepatol doi: 10.1016/j.jhep.2015.11.004 – volume: 12 issue: 3 year: 2021 ident: hep32476-bib-0026-20241017 article-title: Aspirin reduces the incidence of hepatocellular carcinoma in patients with chronic hepatitis B receiving oral nucleos(t)ide analog publication-title: Clin Transl Gastroenterol – volume: 71 start-page: 371 issue: 2 year: 2019 ident: hep32476-bib-0024-20241017 article-title: Prospective evaluation of a primary care referral pathway for patients with non‐alcoholic fatty liver disease publication-title: J Hepatol doi: 10.1016/j.jhep.2019.03.033 – volume: 116 start-page: 1938 issue: 8 year: 2010 ident: hep32476-bib-0009-20241017 article-title: Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma publication-title: Cancer doi: 10.1002/cncr.24982 – volume: 46 start-page: 447 issue: 4 year: 2017 ident: hep32476-bib-0031-20241017 article-title: Laboratory parameter‐based machine learning model for excluding non‐alcoholic fatty liver disease (NAFLD) in the general population publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.14172 – volume: 36 start-page: 4391 issue: 27 year: 2017 ident: hep32476-bib-0015-20241017 article-title: Practical recommendations for reporting Fine‐Gray model analyses for competing risk data publication-title: Stat Med doi: 10.1002/sim.7501 – volume: 5 start-page: 1212 issue: 7 year: 2021 ident: hep32476-bib-0014-20241017 article-title: Colonoscopy and risk of colorectal cancer in patients with nonalcoholic fatty liver disease: a retrospective territory‐wide cohort study publication-title: Hepatol Commun doi: 10.1002/hep4.1705 – volume: 45 start-page: 1097 issue: 11 year: 2010 ident: hep32476-bib-0029-20241017 article-title: Mechanisms by which thiazolidinediones induce anti‐cancer effects in cancers in digestive organs publication-title: J Gastroenterol doi: 10.1007/s00535-010-0310-9 – volume: 155 start-page: 443 issue: 2 year: 2018 ident: hep32476-bib-0022-20241017 article-title: Fibrosis severity as a determinant of cause‐specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi‐national cohort study publication-title: Gastroenterology doi: 10.1053/j.gastro.2018.04.034 – volume: 61 start-page: 409 issue: 3 year: 2012 ident: hep32476-bib-0033-20241017 article-title: Prevalence of non‐alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton‐magnetic resonance spectroscopy and transient elastography publication-title: Gut doi: 10.1136/gutjnl-2011-300342 – volume: 2015 year: 2015 ident: hep32476-bib-0008-20241017 article-title: Diabetes and insulin therapy, but not metformin, are related to hepatocellular cancer risk publication-title: Gastroenterol Res Pract – volume: 74 start-page: 474 issue: 1 year: 2021 ident: hep32476-bib-0032-20241017 article-title: Administrative coding in electronic health care record‐based research of NAFLD: an expert panel consensus statement publication-title: Hepatology doi: 10.1002/hep.31726 – volume: 67 start-page: 328 issue: 1 year: 2018 ident: hep32476-bib-0006-20241017 article-title: The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases publication-title: Hepatology doi: 10.1002/hep.29367 – volume: 67 start-page: 1797 issue: 5 year: 2018 ident: hep32476-bib-0010-20241017 article-title: Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: results from two prospective cohort studies publication-title: Hepatology doi: 10.1002/hep.29660 |
SSID | ssj0009428 |
Score | 2.5523453 |
Snippet | Background and Aims
Several guidelines recommend screening for NAFLD in patients with type 2 diabetes (T2D). We aimed to determine if there is a threshold of... Background and AimsSeveral guidelines recommend screening for NAFLD in patients with type 2 diabetes (T2D). We aimed to determine if there is a threshold of... Several guidelines recommend screening for NAFLD in patients with type 2 diabetes (T2D). We aimed to determine if there is a threshold of age and duration of... |
SourceID | proquest crossref wiley |
SourceType | Aggregation Database Enrichment Source Index Database Publisher |
StartPage | 1409 |
SubjectTerms | Age Aspartate aminotransferase Cirrhosis Diabetes Diabetes mellitus (non-insulin dependent) Fatty liver Fibrosis fibrosis scores Hepatology Liver cancer Liver cirrhosis Liver diseases nonalcoholic steatohepatitis Risk factors type 2 diabetes mellitus |
Title | Risk of liver‐related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhep.32476 https://www.proquest.com/docview/2725989246 https://www.proquest.com/docview/2644020253 |
Volume | 76 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LSwMxEA6lB_HiW6xWieLBy7bb7BtPIi1FUKRY6EFYkk2CpWUr7u6hPfkT_I3-EifZl4qCeFvIhGSTmeSbTOYLQueOBzjBYZEhqPDBQYnA5lxODcuWXkAjblKhEpxv79zh2L6ZOJMGuixzYXJ-iOrATVmGXq-VgVOWdGvS0CcBDjuxPUW3re5qKUA0qqmjAlu_qwpel6miy0HJKmSSblXz615UA8zPMFXvM4NN9Fj2ML9eMutkKetEq2_kjf_8hS20UeBPfJUrzDZqiHgHrd0WEfZdtBpNkxleSDxXFzbeX990sovgWDM9JZgtMaxAmMYcl8e2mGe5GuFpjAue1gSrA95aRMnHCvTrB3mnEZY0TZd5I7gIEu2h8aD_cD00ivcZjMhyfddQTPw9lykSOdMNGDMZ8TgljPkmkdKW3HQksyxHBuDE6Co9XzDfiYgHGiKItY-a0LQ4QBj0A1w_UwjGLJtTylzbFzB3FGRdn_da6KKcqTAqyMvVGxrzMKddJiGMZajHsoXOKtHnnLHjJ6F2Od1hYbRJSDzwBX1wSKH4tCoGc1MxFBqLRQYygB8BYRPHgi7puf29kXDYv9cfh38XPULrRCVY6GzHNmqmL5k4BtiTshOt3x-VfgAX |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NSsQwEB5WBfXiv_hvFA9e6nbTNm3Bi4iy6q6IuLAXKUmT4rJSxXYPevIRfEafxEna7qooiLdCJkyamUlmMsk3AHuej36CJ2JLcRVggBKjzTHJLcdN_JDH0uZKP3BuX7Jmxz3vet0aHFZvYQp8iOGBm7YMs15rA9cH0vURauidwoiduj4bgwld0dsEVNcj8KjQNZVVMe6ydX45rHCFbFofdv26G41czM-OqtlpTmfhthpjccGkfzDIxUH88g2-8b8_MQczpQtKjgqdmYeaShdgsl0m2Rfh5bqX9clDQu71nY331zfz3kVJYsCeMiKeCS5ChKeSVCe3RA4KTSK9lJRQrRnRZ7wjEk2far_f1OTtxSThef5cMCFlnmgJOqcnN8dNqyzRYMUOC5ilwfgbTGgcOZuFQtiC-pJTIQKbJombSNtLhON4SYhxjOnSCJQIvJj6qCSKOsswjqzVChBUEYz-bKWEcFzJuWBuoFB4HGlZIBursF-JKopL_HJdRuM-KpCXaYRzGZm5XIXdIeljAdrxE9FGJe-otNssoj6GgwHGpNi8M2xGi9NpFJ6qhwHSoAuJTjb1HBySEe7vTKLmyZX5WPs76TZMNW_arah1dnmxDtPIyS2uiW_AeP40UJvoBeViyyj7B4eABDQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LSyQxEC58gHhZ3-j6iuLBS2sm3Z1Os6dFHcYnIgoehCbpJOygtLLTc9DT_oT9jf4SK-nuGRUF8daQCkmnqpKqVOorgK04QTshVnlgpBHooOSoc1zLIIxskspcU2lcgvPpGe9cRUfX8fUI_GpyYSp8iMGFm9MMv187BX_QdncIGvrHoMPOooSPwnjEqXAivX8xxI5KI19YFd0u6sLLaQMrRNnuoOvbw2hoYb62U_1B056Cm2aK1fuS251-qXbyp3fojd_8h2n4URug5HclMTMwYopZmDitQ-xz8HTR7d2Se0vu3IuN53__fbaL0cRDPfWIeiS4BRFZaNLc2xLdr-SIdAtSA7X2iLvhHZI4-sJZ_b4ibzcnVpblYzUIqaNE83DVPrjc6wR1gYYgD7nggYPib3HlUOQoT5WiiiVaMqUEZdZGVtPYqjCMbYpejO_SEkaJOGcJiohh4QKM4dBmEQgKCPp-1BilwkhLqXgkDPJOIi0XurUE2w2nsrxGL3dFNO6yCneZZbiWmV_LJdgckD5UkB0fEa007M5qre1lLEFnUKBHis0bg2bUNxdEkYW57yMNGpBoYrM4xCl53n4-SNY5OPcfP79Oug4T5_vt7OTw7HgZJplLtvCZjyswVv7tm1U0gUq15kX9BZr7Auo |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Risk+of+liver%E2%80%90related+events+by+age+and+diabetes+duration+in+patients+with+diabetes+and+nonalcoholic+fatty+liver+disease&rft.jtitle=Hepatology+%28Baltimore%2C+Md.%29&rft.au=Zhang%2C+Xinrong&rft.au=Wong%2C+Grace+Lai%E2%80%90Hung&rft.au=Yip%2C+Terry+Cheuk%E2%80%90Fung&rft.au=Cheung%2C+Johnny+T.+K.&rft.date=2022-11-01&rft.issn=0270-9139&rft.eissn=1527-3350&rft.volume=76&rft.issue=5&rft.spage=1409&rft.epage=1422&rft_id=info:doi/10.1002%2Fhep.32476&rft.externalDBID=n%2Fa&rft.externalDocID=10_1002_hep_32476 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0270-9139&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0270-9139&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0270-9139&client=summon |